

Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Navigating a Therapeutic Triad: A Case of Pulmonary Tuberculosis Complicated by Drug-Induced Liver Injury and Prediabetes

Yuni Kartika^{1*}, Irvan Medison¹, Dessy Mizarti¹

¹Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia

ARTICLE INFO

Keywords:

Anti-tuberculosis agents
Chemical and drug-induced liver injury
Hepatotoxicity
Prediabetes
Pulmonary tuberculosis

*Corresponding author:

Yuni Kartika

E-mail address:

yunikartika01@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i9.1372>

ABSTRACT

Background: The management of pulmonary tuberculosis (TB) is frequently complicated by adverse drug reactions, with drug-induced liver injury (DILI) being one of the most severe. The clinical challenge is significantly amplified in patients with underlying metabolic disorders such as prediabetes, which can impair immune responses and affect treatment outcomes. This report details the complex management of a geriatric patient presenting with this therapeutic triad. **Case presentation:** A 67-year-old male with newly diagnosed, drug-sensitive pulmonary tuberculosis developed severe hepatotoxicity ten days after initiating standard first-line anti-tuberculosis therapy. Clinical presentation included jaundice, nausea, and vomiting, with laboratory findings showing a severe hepatocellular injury pattern (SGOT 204 U/L, SGPT 126 U/L) and hyperbilirubinemia (Total Bilirubin 2.6 mg/dL). Concurrently, he was diagnosed with prediabetes (HbA1c 5.9%) and was suffering from severe malnutrition (BMI 15.6 kg/m²). The offending drugs were immediately withdrawn, and supportive therapy was initiated. Following normalization of liver function, a modified anti-tuberculosis regimen was cautiously reintroduced using a stepwise re-challenge protocol that entirely omitted pyrazinamide. **Conclusion:** The patient was successfully managed with a modified nine-month regimen of isoniazid, rifampicin, and ethambutol, achieving clinical and biochemical stability without recurrence of liver injury. This case highlights that a meticulous, stepwise approach—involving prompt drug withdrawal, supportive care, and a tailored re-challenge protocol—can lead to successful TB treatment outcomes without recurrence of DILI, even in a patient with multiple converging high-risk factors.

1. Introduction

Tuberculosis (TB), the disease caused by the bacillus *Mycobacterium tuberculosis*, remains a persistent and formidable global health adversary. Despite significant progress over the past decades, the World Health Organization (WHO) reported that 10.6 million people fell ill with TB in 2023, leading to 1.3 million deaths, which reaffirms its position as a leading cause of mortality from a single infectious agent worldwide.¹ The bedrock of global TB control is effective chemotherapy. The standard, highly efficacious six-month regimen for drug-susceptible TB consists of a combination of four first-line drugs:

isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB).² While this regimen can cure the vast majority of patients, its success is often shadowed by the risk of significant adverse effects. Among the potential complications, anti-tuberculosis treatment-induced drug-induced liver injury (ATT-DILI) stands out as one of the most serious and potentially life-threatening. Three of the four cornerstone drugs—INH, RIF, and PZA—possess intrinsic hepatotoxic potential. The incidence of ATT-DILI varies widely across global populations, reported to be between 2% and as high as 39%, influenced by a constellation of host and environmental factors.^{3,4}

Established risk factors include advanced age, chronic alcohol use, pre-existing liver conditions like viral hepatitis or cirrhosis, and certain genetic polymorphisms, most notably the N-acetyltransferase 2 (NAT2) gene, which governs INH metabolism and can result in a "slow acetylator" phenotype that predisposes to toxicity.⁵ The onset of DILI presents a profound clinical dilemma: continuing treatment may precipitate fulminant hepatic failure, while premature cessation risks treatment failure, disease progression, and the amplification of drug resistance.

The clinical landscape becomes exponentially more complex when metabolic disorders coexist with TB. The syndemic of TB and diabetes mellitus (DM) is a well-recognized global health crisis; individuals with DM face a two- to three-fold greater risk of progressing from latent TB infection to active disease.⁶ More recently, prediabetes—an intermediate state of hyperglycemia where blood glucose levels are elevated but do not meet the criteria for DM—has been identified as an independent and significant risk factor.⁷ The pathophysiological link is rooted in immunological dysfunction; even modest hyperglycemia can impair crucial host defenses against *M. tuberculosis*. This includes hampering neutrophil chemotaxis and phagocytosis, reducing the bactericidal capacity of macrophages, and skewing the adaptive immune response towards a less effective, pro-inflammatory state with diminished production of key cytokines like interferon-gamma (IFN- γ).⁸ Consequently, patients with prediabetes may experience poorer TB treatment outcomes, including delayed sputum culture conversion and a higher risk of relapse.

This case report details the management of a patient who embodied a perfect storm of clinical vulnerabilities: a geriatric individual with active pulmonary TB, who developed severe DILI shortly after starting treatment, and was concurrently diagnosed with both prediabetes and severe malnutrition. This confluence of infection, iatrogenic injury, and metabolic dysregulation creates a "therapeutic triad" of immense complexity, where each condition

negatively influences the others. The inflammatory cascade of TB can exacerbate insulin resistance and worsen glycemic control; the prediabetic state weakens the immune armamentarium needed to fight the infection; malnutrition depletes the physiological reserves required to tolerate toxic medications; and the resultant DILI threatens the patient's immediate survival while jeopardizing the only available cure. While clinical guidelines for managing ATT-DILI exist, there is a scarcity of data detailing their application in patients burdened with this specific combination of high-risk factors. The novelty of this report, therefore, lies in its detailed, evidence-informed description of a successful, stepwise management strategy that navigated this intricate interplay. The aim of this case report is to provide a practical and reproducible framework for clinicians faced with this challenging scenario, with a particular focus on the rationale and execution of a modified re-challenge protocol in a geriatric, malnourished patient with underlying metabolic dysfunction.

2. Case Presentation

A 67-year-old male presented in a state of profound medical crisis, a condition meticulously captured by the clinical dashboard in Figure 1. This dashboard does not merely list data; it paints a vivid, multi-system portrait of a patient at the nexus of three colliding pathologies: a debilitating infectious disease, a severe iatrogenic organ injury, and a deep-seated metabolic and nutritional collapse. Each data point on this dashboard is a crucial piece of a complex puzzle, and together they narrate the story of a body waging a war on multiple fronts, where every physiological system is interconnected and compromised. The initial panel, "Patient Profile & Vitals," immediately establishes the high-risk context. At 67 years of age, the patient falls into a geriatric demographic inherently associated with increased vulnerability. This "High Risk" designation is not arbitrary; it reflects the well-documented physiological changes of aging, including immunosenescence—a gradual decline in immune system efficacy—and altered

pharmacokinetics, where changes in liver and kidney function can slow drug metabolism and clearance, predisposing to toxicity. His medical history, notable for the absence of smoking and alcohol consumption, is critically important as it systematically eliminates two of the most common confounding factors for both liver and lung disease, thereby sharpening the focus on the primary pathologies at hand. His vital signs on admission depicted a state of compensated stress. A blood pressure of 110/70 mmHg, while within the normal range, sits at the lower end, hinting at his frail and possibly volume-depleted state. The heart rate of 100 beats per minute represents a mild tachycardia, a subtle but significant sign of the body's attempt to compensate for the systemic inflammatory response driven by his infection, the discomfort from his acute hepatitis, or both. Similarly, a respiratory rate of 20 breaths per minute, at the upper limit of normal, directly reflects the underlying pulmonary disease compromising his respiratory function. Notably, he was afebrile with a temperature of 36.8°C. In a geriatric and malnourished patient, the absence of fever can be misleading; such individuals often fail to mount a robust febrile response, and a normal temperature cannot be misinterpreted as the absence of severe infection. Moving from the vital signs to the patient's foundational health, the "Metabolic & Nutritional Crisis" panel reveals the depth of his physiological depletion. This is the bedrock of his vulnerability. The diagnosis of Severe Malnutrition is unequivocally established by two key metrics. His Body Mass Index (BMI) of 15.6 kg/m² is drastically low, indicating profound wasting of both muscle and fat stores—a state of cachexia that has severely eroded his physiological reserves. This is not merely a number but a physical manifestation of his body consuming itself to fuel the fight against a chronic infection. This external sign of wasting is mirrored by the internal biochemical evidence: a serum albumin level of 2.9 g/dL. Hypoalbuminemia is a powerful indicator of poor visceral protein status and compromised hepatic synthetic function. Albumin is essential for maintaining plasma oncotic pressure and

transporting substances in the blood. In the context of this case, its deficiency is catastrophic, as it signifies a depleted pool of amino acid precursors necessary for synthesizing glutathione, the liver's master antioxidant and primary defense against drug-induced toxicity. This nutritional crisis created a defenseless host, unable to withstand the chemical insult of his medications.

Compounding this nutritional collapse is the Metabolic Derangement diagnosed as Prediabetes, confirmed by a Glycated Hemoglobin (HbA1c) of 5.9%. This finding reveals a state of chronic, intermediate hyperglycemia that has been present for at least two to three months. This is a critical piece of the puzzle, illustrating the bidirectional and destructive relationship between tuberculosis and metabolic disease. His underlying prediabetic state, characterized by insulin resistance, would have impaired his immune response, making him more susceptible to the reactivation or progression of his TB infection. Conversely, the intense inflammatory stress from the active TB infection would have exacerbated his insulin resistance, pushing his blood glucose levels higher and worsening his metabolic control. This patient was trapped in a vicious cycle where his infection fueled his metabolic disease, and his metabolic disease weakened his ability to fight the infection. The final and most acute part of the dashboard, the "Organ System Profile: Hepatic & Pulmonary," details the two primary battlegrounds where this crisis was unfolding. The diagnosis of Severe Drug-Induced Hepatitis is starkly illustrated by the liver function tests. The aspartate aminotransferase (SGOT/AST) of 204 U/L and alanine aminotransferase (SGPT/ALT) of 126 U/L are not just elevated; they are markers of significant, ongoing hepatocyte necrosis, indicating that liver cells were actively dying and releasing their intracellular enzymes into the bloodstream. The total bilirubin of 2.6 mg/dL confirms that the liver's damage was not only cytotoxic but also functional, as it had lost its ability to effectively process and excrete bilirubin, leading to the clinical jaundice observed in the patient.

anatomical correlation to this diagnosis. The chest radiograph showing "left-sided consolidation & moderate pleural effusion" visualizes the extent of the lung destruction caused by the mycobacteria. The abdominal ultrasound served a critical role in the diagnostic process; by showing a normal liver parenchyma and confirming the absence of biliary obstruction, it effectively ruled out other common causes of jaundice and liver failure, thereby solidifying the diagnosis of DILI by exclusion. Every piece of data in this section is interconnected, weaving a coherent story of a lung infection leading to a necessary but toxic treatment, which in turn caused a severe liver injury, with all signs and symptoms aligning perfectly, as presented in Figure 1.




Figure 2 showed a meticulously designed and elegantly visualized clinical pathway, a strategic roadmap that guided the patient through the perilous terrain of his complex illness. This figure is more than a mere flowchart; it is a narrative of clinical decision-making, illustrating a dynamic, three-phased journey from the precipice of acute organ failure to the stable path of long-term recovery and cure. Each phase, denoted by a distinct color and icon, represents a different chapter in the patient's story, with specific actions, rationales, and monitoring protocols that were scientifically grounded and precisely tailored to his unique set of vulnerabilities. The pathway demonstrates a masterful blend of aggressive intervention, calculated caution, and sustained vigilance, providing a clear and reproducible framework for managing one of the most challenging scenarios in modern internal medicine and pulmonology. The journey begins with Phase 1: Acute DILI Management, depicted in a stark, cautionary red, symbolizing the imminent danger and the urgent need for decisive action. This nine-day in-hospital period, from Day 1 to Day 9, represented the most critical phase of the patient's care, where the primary objective was to halt the progression of a life-threatening iatrogenic injury and stabilize the patient. The "Primary Action" listed is absolute and non-negotiable in the face of severe drug-induced hepatitis: the immediate cessation of all four anti-tuberculosis drugs. This is the single most important intervention, predicated on the fundamental toxicological principle of removing the offending agent. In this patient, the combination of isoniazid, rifampicin, and pyrazinamide was acting as a potent chemical poison to the liver. Continuing this onslaught, even for another day, would have risked pushing his already damaged liver over the edge into fulminant hepatic failure—a condition with catastrophically high mortality. This action, supported unequivocally by all major international guidelines from the American Thoracic Society, British Thoracic Society, and European Association for the Study of the Liver, was the essential first step to give the liver a chance to

begin the arduous process of healing and regeneration. With the toxic assault halted, the focus immediately shifted to comprehensive Supportive Care, a multi-pronged strategy designed to create the optimal physiological environment for recovery. "Intravenous hydration" was crucial to correct the dehydration resulting from his persistent vomiting and poor oral intake, ensuring adequate circulatory volume and, critically, maintaining renal perfusion to prevent a secondary insult in the form of acute kidney injury. The most foundational element of this supportive care was the "Aggressive nutritional rehabilitation." For this patient, who was in a state of severe malnutrition, this was not an ancillary treatment but a life-saving therapy. His depleted protein stores meant he lacked the essential amino acid building blocks—cysteine, glycine, and glutamate—required for the synthesis of glutathione, the liver's master antioxidant. This glutathione deficiency had left his hepatocytes defenseless against the toxic metabolites of his medications. The prescribed high-calorie, high-protein diet was designed to reverse his profound catabolic state, providing the necessary substrates to replenish his glutathione stores, synthesize new hepatocyte proteins, and produce albumin to correct his hypoalbuminemia and restore plasma oncotic pressure. Finally, the "Therapeutic thoracentesis," which drained 400 cc of fluid, served a dual purpose: it was therapeutic, relieving the compression on his left lung to improve his work of breathing, and it was diagnostic, allowing for analysis of the fluid to confirm its nature and rule out other pathologies. Throughout this critical phase, the patient was under a strict Monitoring Protocol. The "Daily clinical assessment" was essential to track his symptoms, while the "serial Liver Function Tests (LFTs) every 48-72 hours" provided an objective biochemical window into the liver's response. This frequent monitoring was the team's navigation system; a steady decline in transaminases and bilirubin would signal a positive "de-challenge" and a favorable prognosis. Conversely, stagnating or rising LFTs would have been an ominous

sign of ongoing liver necrosis, necessitating an escalation of care and consultation with transplant hepatology services. This vigilant monitoring ensured that the clinical team could react in real-time to the patient's dynamic and fragile condition.

Having successfully navigated the acute crisis, the clinical pathway transitions to Phase 2: Cautious ATT Re-challenge, symbolized by the calm, controlled blue of methodical medical intervention. This period, from Day 10 to Day 18, represented the most intellectually and clinically challenging part of the patient's management. The team had to thread a delicate therapeutic needle: reintroducing the life-saving anti-tuberculosis drugs required to cure his underlying infection, while simultaneously avoiding a recurrence of the devastating liver injury. The entire strategy for this phase was predicated on one Key Decision, highlighted prominently in the figure: Pyrazinamide (PZA) was permanently omitted. This was the central strategic pivot of the entire treatment plan. PZA is known to be the most hepatotoxic of the first-line agents, with a dose-dependent effect that is significantly amplified in patients with pre-existing risk factors like malnutrition and advanced age. By definitively removing PZA from the equation, the overall hepatotoxic potential of the regimen was dramatically reduced, creating a much wider margin of safety for the re-challenge. This decision, however, carried a necessary consequence that would influence the final phase of treatment: the total duration of therapy would need to be extended from six to nine months to compensate for the loss of PZA's potent early sterilizing activity. With this key decision made, the team initiated the Stepwise Re-introduction Schedule, a classic pharmacological strategy designed to test the patient's tolerance and minimize risk. The re-challenge did not begin with the most powerful drugs, but with the safest. Step 1 (Days 10-12) involved the introduction of Ethambutol (E) at its full therapeutic dose. Ethambutol is widely considered to be the least hepatotoxic of the core anti-tuberculosis drugs and is almost never implicated as a sole cause of severe DILI. Its successful introduction provided a

safe and stable baseline upon which to build the rest of the regimen. Following this, Step 2 (Days 13-15) saw the reintroduction of Isoniazid (H), a known major culprit in ATT-DILI. The approach here was one of extreme caution. Instead of starting at the full dose, the drug was introduced in an escalating fashion, beginning at a low dose of 100mg and titrating upwards over three days to the full therapeutic dose of 300mg. This dose escalation strategy is critical; it allows the liver's metabolic pathways to gradually adapt to the drug and provides the clinical team with an opportunity to detect any early signs of intolerance—such as a mild rise in LFTs or the recurrence of nausea—before severe, irreversible damage can occur. The final and most crucial step of the re-challenge was Step 3 (Days 16-18), the reintroduction of Rifampicin (R). Rifampicin is not only hepatotoxic in its own right but is also a potent inducer of the cytochrome P450 enzyme system, particularly CYP2E1. This enzyme induction can accelerate the metabolism of isoniazid into its more toxic metabolites, creating a synergistic hepatotoxicity. Therefore, introducing rifampicin last and with the same cautious dose escalation was paramount to safety. The patient's successful tolerance of this final step was the ultimate proof of concept for the modified regimen. Throughout this entire nine-day process, the monitoring was relentless, with LFTs checked before the introduction of each new drug, serving as a critical safety checkpoint to ensure that the previously added drug was well-tolerated before proceeding to the next level of complexity.

With the successful completion of the re-challenge, the patient's journey transitioned into its final and longest chapter, Phase 3: Continuation & Follow-up, aptly symbolized by the green icon of stability, growth, and long-term health. This phase, extending over nine months post-discharge, represented the shift from acute crisis management to the disciplined, outpatient pursuit of a definitive cure. The Final Treatment Regimen was now established: a combination of Isoniazid 300mg, Rifampicin 450mg, and Ethambutol

1000mg, to be taken daily. The 9-Month Total Duration was a direct and necessary consequence of the decision to omit PZA, ensuring that the remaining drugs had sufficient time to eradicate all dormant and persistent mycobacteria, thereby minimizing the risk of a future relapse. The success of this long-term phase depended on a robust Biochemical Monitoring Schedule. The plan for more intensive monitoring in the first month post-discharge, with LFTs checked every two weeks, was designed to detect any delayed-onset hepatotoxicity as the drugs reached their steady-state concentrations in the body. After this initial period of heightened vigilance, the monitoring was de-escalated to a monthly schedule for the remainder of the treatment. This risk-stratified approach balanced the need for safety with the practical considerations of long-term outpatient care. Finally, the entire protocol was scaffolded by continuous Clinical Follow-up & Counseling. Monthly consultations with a pulmonologist were scheduled to assess clinical response, such as weight gain and resolution of respiratory symptoms, and to monitor for other potential long-term side effects of the medications, like peripheral neuropathy from isoniazid or ocular toxicity from ethambutol. Crucially, this phase heavily emphasized patient empowerment. The "ongoing patient & family education on DILI warning signs" transformed the patient and his wife from passive recipients of care into active, informed partners in his treatment. They were taught to recognize the early symptoms of liver trouble, providing an invaluable real-world safety net. Furthermore, the "lifestyle and dietary counseling for prediabetes management" addressed his underlying metabolic condition, using the opportunity of his recovery to set him on a path towards better long-term health and reducing his future risk of progressing to overt diabetes and its associated complications.

3. Discussion

This case report presents a detailed narrative of the successful management of a patient trapped at the

confluence of three competing pathologies: an aggressive infectious disease, a severe iatrogenic injury, and a profound metabolic disturbance. The clinical course of this 67-year-old man with pulmonary tuberculosis, complicated by severe drug-induced liver injury and underscored by prediabetes and malnutrition, serves as a powerful illustration of the principles of individualized medicine. The favorable outcome was not a matter of chance but the result of a deliberate, systematic, and pathophysiologically-informed strategy. This discussion aims to deconstruct the intricate web of clinical reasoning and scientific principles that guided the patient's care, moving from the formal diagnosis of DILI to a deep exploration of the synergistic pathologies at play, and finally, to a critical analysis of the therapeutic decisions made. The initial and most crucial step in the patient's management was the accurate and swift diagnosis of drug-induced liver injury. In clinical practice, DILI is a diagnosis of exclusion, often made with a degree of uncertainty.⁹ However, in this case, the evidence coalesced to form a compelling and definitive picture. The diagnosis was built on three pillars: the temporal sequence of events, the characteristic biochemical signature, and the meticulous exclusion of alternative etiologies. The patient's symptoms of hepatotoxicity began a mere ten days after the initiation of anti-tuberculosis therapy, a classic latency period for idiosyncratic DILI, which most often occurs within the first two months of treatment initiation. This temporal fingerprint is a strong indicator of causality.¹⁰ The biochemical profile, with a greater than five-fold elevation in AST and a greater than three-fold elevation in ALT alongside significant hyperbilirubinemia, pointed towards a severe, mixed hepatocellular-cholestatic pattern of injury.¹¹ This pattern is well-described with the combination of isoniazid, rifampicin, and pyrazinamide. The final pillar was the comprehensive exclusion of other causes. Negative serologies for viral hepatitis A, B, and C, along with a negative HIV test, ruled out the most common infectious confounders.

Clinical Pathway for Treatment & Follow-up




Figure 2. Clinical pathway for treatment & follow-up.

The normal abdominal ultrasound was particularly critical, as it definitively excluded biliary obstruction, hepatic congestion from a cause like Budd-Chiari syndrome, and pre-existing structural liver diseases

like cirrhosis, any of which could have mimicked or predisposed the patient to this presentation.¹² To elevate the diagnostic certainty from clinical suspicion to a formal, scientifically robust conclusion, the

Roussel Uclaf Causality Assessment Method (RUCAM) was applied. This validated scoring system is the international standard for assessing DILI causality. The patient's case scored a total of 10 points: a score of +2 for the temporal relationship (onset within 5-90 days), +3 for the rapid improvement upon drug withdrawal (a >50% decrease in ALT within eight days), +1 for the age-related risk factor (≥ 55 years), +2 for the comprehensive exclusion of alternative causes, and +2 for the known and labeled hepatotoxic potential of the prescribed drugs.¹³ A score of 10 firmly places the causality in the "Highly Probable" category, providing a definitive etiological anchor for all subsequent management decisions. This rigorous diagnostic process was not merely an academic exercise; it was the foundation upon which the entire therapeutic strategy was built, justifying the immediate cessation of all anti-tuberculosis drugs and the subsequent design of a safer, modified regimen.¹⁴

The severity of this patient's illness can only be understood by appreciating the catastrophic synergy between his multiple underlying vulnerabilities.¹⁵ He was not simply a patient with three separate problems; he was a patient whose conditions were locked in a vicious, self-amplifying cycle. This "perfect storm" was fueled by the intersecting axes of geriatric frailty, metabolic dysfunction, and infectious inflammation. The patient's advanced age and severe nutritional depletion were arguably the most critical factors predisposing him to DILI. The aging liver undergoes a process of immunosenescence and physiological decline.¹⁶ There is a documented reduction in hepatic volume, a decrease in splanchnic blood flow, and a diminished functional capacity of the cytochrome P450 enzyme system. These age-related changes, often referred to as "pharmacogeriatrics," lead to slower drug metabolism and clearance, increasing the half-life of both parent drugs and their metabolites, thereby heightening the risk of toxic accumulation. This inherent, age-related vulnerability was catastrophically amplified by his state of severe protein-energy malnutrition, as evidenced by his BMI of 15.6 kg/m² and profound hypoalbuminemia. The

biochemical link between malnutrition and DILI is direct and devastating. The liver's primary defense against chemical insults is the tripeptide antioxidant, glutathione (GSH).¹⁷ During the metabolism of isoniazid, a portion is converted via the CYP2E1 enzyme into highly reactive, toxic intermediates, principally hydrazine and acetylhydrazine. In a healthy, well-nourished individual, these toxic metabolites are rapidly neutralized through conjugation with GSH and safely excreted. However, in a state of protein malnutrition, the body's synthesis of GSH is severely impaired due to the lack of precursor amino acids (cysteine, glycine, and glutamate). This patient's malnourished state meant his hepatocytes were effectively stripped of their primary detoxification shield. The toxic metabolites of isoniazid, instead of being neutralized, were free to wreak havoc, covalently binding to cellular proteins and lipids, triggering immense oxidative stress, inducing mitochondrial dysfunction, and ultimately initiating the cascade of hepatocyte apoptosis and necrosis that manifested as his acute liver failure. His liver was, in a very real sense, chemically defenseless. The concurrent diagnosis of prediabetes introduced another insidious layer of risk. Chronic hyperglycemia, even at the sub-diabetic levels seen in prediabetes, is not a benign condition.¹⁸ It fosters a systemic state of chronic, low-grade, sterile inflammation, a phenomenon now widely recognized as "meta-inflammation." This state is characterized by the chronic activation of innate immune cells and the elevated production of pro-inflammatory cytokines such as TNF- α and IL-6. This pre-existing inflammatory "tone" creates a liver environment that is already primed for injury. When a second inflammatory hit occurs—in this case, the acute, potent pro-inflammatory cascade triggered by the active TB infection—the result can be a dysregulated and exaggerated inflammatory response, leading to greater collateral tissue damage. Furthermore, hyperglycemia directly inflicts damage on hepatocytes through several mechanisms. It induces cellular oxidative stress by increasing the flux through the

polyol pathway and promoting the formation of advanced glycation end-products (AGEs). These AGEs can activate receptors on hepatic stellate cells and Kupffer cells, further promoting a pro-inflammatory and pro-fibrotic environment.¹⁸ In essence, the patient's prediabetic state made his hepatocytes intrinsically more vulnerable and less resilient, pre-sensitizing them to the "second hit" delivered by the hepatotoxic drugs. It lowered the threshold for injury, meaning a dose of medication that a metabolically healthy individual might have tolerated proved to be devastatingly toxic for him. The final component of this triad was the active TB infection itself. A high-burden infectious disease like pulmonary TB is a profound metabolic stressor.¹⁹ The body's response involves the massive release of counter-regulatory stress hormones, principally cortisol and glucagon, as well as inflammatory cytokines like TNF- α . These mediators have potent metabolic effects: they promote hepatic gluconeogenesis and glycogenolysis while simultaneously inducing a state of peripheral insulin resistance. This is a physiological adaptation designed to shuttle glucose to the immune system, but in an individual with pre-existing metabolic fragility, it can have disastrous consequences. In this patient, the inflammatory stress of his TB infection almost certainly acted as the trigger that overwhelmed his compromised pancreatic beta-cell function, unmasking his latent prediabetes and pushing him into a state of overt hyperglycemia. This completes the vicious cycle: the infection worsened his metabolic state, the metabolic state weakened his immune response and primed his liver for injury, and the drugs required to treat the infection delivered the final, toxic blow to the now-defenseless organ. Understanding this intricate, multi-directional interplay of pathologies is essential to appreciating why a multifaceted and highly individualized therapeutic approach was not just optimal, but absolutely necessary for his survival.

Figure 3 showed a masterfully rendered schematic that deconstructs the devastating cascade of events leading to this patient's acute organ failure. It is not

merely a diagram but a profound visual narrative of a "pathophysiological triad," a conceptual model that explains how three distinct domains of insult—Host Vulnerability, Infectious Burden, and Iatrogenic Insult—converged with catastrophic synergy. The figure's elegant design, with its cascade-like flow, visually articulates a story of how a pre-existing state of fragility was mercilessly amplified by both a biological and a chemical assault, culminating in the final common pathway of severe organ injury. By dissecting this triad, we can appreciate the intricate and interwoven mechanisms that transformed a treatable infectious disease into a life-threatening medical emergency. At the apex of this cascade, serving as the foundational layer of risk, is the domain of Host Vulnerability. This panel, depicted in a cautionary amber, encapsulates the intrinsic and acquired weaknesses that rendered this patient uniquely susceptible to harm. It details a state of profound physiological compromise long before the first dose of medication was administered. The first element, the Intrinsic State, points to the unmodifiable factors of geriatric age and the modifiable but chronic condition of prediabetes. At 67 years of age, the patient was subject to the physiological realities of immunosenescence, a well-documented, age-related decline in the robustness of both the innate and adaptive immune systems. This manifests as a blunted response to pathogens and a diminished capacity for tissue repair. Concurrently, the diagnosis of prediabetes signifies a state of chronic "meta-inflammation." This is not a benign metabolic state but a low-grade, sterile inflammatory condition where organs, including the liver, are continuously exposed to elevated levels of pro-inflammatory cytokines like TNF- α and IL-6. This chronic inflammation creates a hostile microenvironment, effectively "priming" the hepatocytes and making them hyper-responsive to any subsequent inflammatory or toxic trigger. The second, and perhaps most critical, element of his vulnerability was the Nutritional Deficit. His severe malnutrition was not merely a matter of weight loss; it was a profound biochemical crisis that

crippled his body's primary defense system against chemical toxicity.




Figure 3. The pathophysiology triad of organ injury.

The liver's master antioxidant, the tripeptide Glutathione (GSH), is the single most important molecule for neutralizing the reactive metabolites produced during the metabolism of drugs like isoniazid. GSH synthesis is an energy-intensive process that is wholly dependent on an adequate supply of precursor amino acids—cysteine, glutamate, and glycine—which are obtained from dietary protein. In this patient's state of severe protein-energy malnutrition, his visceral protein stores were depleted, and his capacity to synthesize new GSH was critically impaired. This Glutathione depletion left his

hepatocytes biochemically naked and defenseless against the inevitable onslaught of toxic byproducts from his anti-tuberculosis therapy. His host vulnerability was therefore a house of cards: a senescent immune system, a chronically inflamed liver, and a chemically undefended cellular environment, all waiting for a force strong enough to cause a total collapse. The first of these forces is detailed in the second panel, the Infectious Burden. Depicted in a virulent teal, this represents the active, high-burden pulmonary tuberculosis that served as the primary inflammatory engine of his illness. The

"High Bacillary Load" signifies a florid, uncontrolled infection that was provoking a massive systemic immune response. This response, while necessary to fight the pathogen, is a double-edged sword. It triggers a potent systemic inflammatory cascade, flooding the body with the same pro-inflammatory cytokines, TNF- α and IL-6, that were already elevated due to his meta-inflammation. This created an amplified, dysregulated inflammatory state that could cause significant collateral damage to bystander organs, including the liver. Furthermore, the figure correctly identifies the TB infection as a powerful Metabolic Stressor. The systemic inflammation drives the release of counter-regulatory hormones like cortisol and glucagon, which directly antagonize the action of insulin. This induces a state of severe insulin resistance, causing his blood glucose levels to spike. This hyperglycemia, in turn, fueled the fire of his pre-existing metabolic dysfunction, creating a destructive, vicious cycle: the TB infection worsened his hyperglycemia, and the hyperglycemia impaired his immune cells' ability to effectively kill the *M. tuberculosis* bacilli. This infectious burden was therefore not just a lung disease; it was a systemic event that actively degraded his metabolic health and intensified the inflammatory pressure on his already vulnerable liver. Into this perfect storm of a vulnerable host and a raging infection came the final, decisive blow: the Iatrogenic Insult, depicted in a clinical purple. This panel represents the necessary but perilous introduction of the hepatotoxic anti-tuberculosis therapy (ATT). The standard four-drug regimen, containing isoniazid, rifampicin, and pyrazinamide, is a powerful chemical cocktail designed to kill mycobacteria, but it comes at a cost. During their metabolism in the liver, these drugs generate a massive load of reactive drug metabolites. Isoniazid produces hydrazine; rifampicin, a potent inducer of the CYP450 enzymes, accelerates this toxic conversion; and pyrazinamide produces pyrazinoic acid, which disrupts mitochondrial function. In a healthy individual with robust GSH stores, these metabolites are swiftly neutralized. In this patient, however, they flooded a system with no

capacity to defend itself. This represents the classic "second hit" in the pathogenesis of liver injury. His underlying vulnerability—the malnutrition, prediabetes, and advanced age—constituted the "first hit," which had already sensitized and weakened the liver. The introduction of the hepatotoxic drugs was the "Second Hit," a chemical insult that the compromised organ simply could not withstand. The figure astutely notes that this chemical insult "overwhelms the liver's compromised defenses, delivering the final blow." The reactive metabolites, finding no glutathione to neutralize them, began to bind indiscriminately to cellular proteins and lipids, triggering a cascade of destruction. The downward arrow, labeled Synergistic Amplification, is perhaps the most important conceptual element of the entire schematic. It illustrates that these three factors did not merely add to one another; they multiplied each other's destructive potential.¹⁹ The inflammation from the TB infection exacerbated the metabolic damage from prediabetes. The malnutrition crippled the liver's ability to handle the drugs. The synergistic toxicity of the drugs themselves was amplified by the pre-existing inflammation. This synergy explains why the patient developed such severe DILI so rapidly. It was not a simple case of drug toxicity; it was a multifactorial systemic collapse. This cascade culminates in the final, ominous red panel at the bottom of the figure: Severe Drug-Induced Liver Injury, described with devastating accuracy as The Final Common Pathway. This is the tragic endpoint where all three streams of pathology converge. The schematic details the key cellular events of this final pathway: overwhelming oxidative stress from the un-neutralized reactive metabolites, leading to widespread lipid peroxidation and membrane damage; critical mitochondrial injury, which cripples the cell's ability to produce ATP and can trigger the intrinsic pathway of apoptosis, or programmed cell death; and finally, widespread hepatocyte necrosis, the ultimate outcome of these insults, where liver cells die en masse, releasing their contents into the bloodstream and leading to the clinical picture of acute hepatic failure.

The management of this patient was a masterclass in navigating a therapeutic tightrope, balancing the urgent need to control a life-threatening infection against the equally urgent need to prevent fatal liver failure. The chosen strategy was built on a foundation of established guidelines but was critically adapted to the patient's unique set of vulnerabilities.²⁰ The decision to reintroduce anti-tuberculosis therapy after the resolution of the acute DILI was the most critical juncture in his care. Withholding treatment was not an option, as untreated, high-burden pulmonary TB in a frail, elderly patient would have been universally fatal. The cornerstone of the re-challenge strategy was the permanent omission of pyrazinamide. PZA is known to be the most hepatotoxic of the first-line agents, with a dose-dependent effect that is particularly pronounced in patients with any underlying liver pathology or risk factors. By removing PZA from the regimen, the overall hepatotoxic load was immediately and dramatically reduced.²⁰ This single decision was likely the most important factor in the success of the re-challenge. The re-challenge protocol itself was a model of clinical prudence. The sequential, one-by-one reintroduction of the remaining drugs, starting with the least hepatotoxic agent (ethambutol), is the standard of care. This approach serves a dual purpose: it minimizes the risk of a severe, rapid recurrence of DILI, and it allows for the potential identification of a single offending agent if a reaction were to occur. The gradual, escalating dosage of isoniazid and then rifampicin further tested the patient's metabolic capacity to handle these drugs. His successful tolerance of the full three-drug regimen provided strong evidence that his initial DILI was a result of the cumulative, synergistic toxicity of the standard four-drug combination, rather than a specific hypersensitivity to either INH or RIF alone. The synergistic toxicity of INH and RIF is a well-established phenomenon—RIF is a potent inducer of the CYP2E1 enzyme, which accelerates the conversion of INH into its toxic hydrazine metabolites. The addition of PZA to this mix creates a level of hepatotoxic stress that this patient's compromised

liver simply could not withstand. The final therapeutic regimen—two months of rifampicin, isoniazid, and ethambutol, followed by seven months of rifampicin and isoniazid (a total of nine months)—is a well-established and internationally recommended alternative for patients who cannot tolerate pyrazinamide. Rifampicin is the most powerful sterilizing drug in the arsenal against TB, and its inclusion for the entire nine-month duration is essential for ensuring a high rate of cure and preventing relapse.²⁰ While longer than the standard six-month regimen, this nine-month duration is necessary to compensate for the absence of the early sterilizing activity of PZA. This decision represented a carefully considered trade-off, accepting a longer treatment duration in exchange for a significantly enhanced safety profile. This patient-centered approach, which prioritized safety while adhering to the core principles of TB chemotherapy, was ultimately the key to successfully guiding him through this perilous clinical journey.

4. Conclusion

This case report chronicles the successful management of a patient facing a trifecta of life-threatening conditions: active pulmonary tuberculosis, severe drug-induced liver injury, and the compounding metabolic insults of prediabetes and malnutrition. The convergence of these pathologies in a single, frail, geriatric individual created a clinical scenario of extreme complexity and high risk. The favorable outcome was not happenstance but the direct result of a dynamic, vigilant, and highly individualized therapeutic strategy. This case compellingly demonstrates that even in the face of such daunting clinical challenges, a positive result is achievable. The core principles underpinning this success were the unequivocal and immediate withdrawal of all offending medications, the aggressive implementation of supportive care focused on nutritional rehabilitation, and most critically, the meticulous and cautious reintroduction of a modified, pyrazinamide-sparing anti-tuberculosis regimen. By

tailoring the treatment to the patient's unique physiological limitations and extending the duration to ensure microbiological cure, it was possible to navigate the narrow therapeutic window between controlling the infection and preventing fatal organ damage. This narrative provides a powerful, real-world testament to the fact that in modern medicine, the most effective protocols are not merely followed, but are thoughtfully adapted to the intricate biological and clinical tapestry of the individual patient. It stands as an informative guide for clinicians who may face this or similar complex therapeutic dilemmas, reinforcing the paramount importance of personalized care in achieving healing against all odds.

5. References

1. Wong R, Rupp LB, Lu M, Yang Z, Daida YG, Schmidt MA, et al. S1208 prevalence of hepatitis B virus (HBV) and latent tuberculosis co-infection and risk of drug-induced liver injury across two large HBV cohorts in the United States. *Am J Gastroenterol*. 2022; 117(10S): e878–9.
2. Chou C, Veracruz N, Chitnis AS, Wong RJ. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. *J Viral Hepat*. 2022; 29(12): 1107–14.
3. Chen Q, Hu A, Ma A, Jiang F, Xiao Y, Chen Y, et al. Effectiveness of prophylactic use of hepatoprotectants for tuberculosis drug-induced liver injury: a population-based cohort analysis involving 6,743 Chinese patients. *Front Pharmacol*. 2022; 13: 813682.
4. Ratnansari Giri R, Suryana K. Drug-induced liver injury after anti tuberculosis drugs administration, how to diagnose? a case report. *Int J Adv Med*. 2022; 9(9): 951.
5. Lee S, Yi N-J, Kwak N, Kim H, Hong SY, Lee J-M, et al. Immune reconstitution inflammatory syndrome and drug-induced liver injury during treatment of disseminated tuberculosis in a liver transplant recipient: a case report. *Transplant Proc*. 2023; 55(8): 1972–4.
6. D Freire I, L Fielding K, A J Moore D. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment? *PLoS One*. 2023; 18(5): e0286306.
7. Wong RJ, Rupp L, Lu M, Yang Z, Daida YG, Schmidt M, et al. Prevalence of hepatitis B virus (HBV) and latent tuberculosis co-infection and risk of drug-induced liver injury across two large HBV cohorts in the United States. *J Viral Hepat*. 2023; 30(6): 512–9.
8. Dong H, Feng J, Chang X, Wu S, Tang G, Liang F, et al. Predictive value of systemic immune-inflammatory biomarkers for drug-induced liver injury in hepatitis B virus surface antigen positive tuberculosis patients: a retrospective observational study. *Medicine (Baltimore)*. 2024; 103(45): e40349.
9. Abdul M, Nikitin IG, Alieva SA, Zheldibaeva UT, Kasymkan AE, Adilgozhina SM, et al. Drug-induced liver injury in HIV-infected patients with active tuberculosis: Comparative. *Sci Healthc*. 2024; (6(26)): 64–71.
10. Boyles T, Berhanu RH, Gogela N, Gunter H, Lovelock T, Mphothulo N, et al. Management of drug-induced liver injury in people with HIV treated for tuberculosis: 2024 update. *South Afr J HIV Med*. 2024; 25(1): 1558.
11. Xiao Y, Chen Y, Huang R, Jiang F, Zhou J, Yang T. Interpretable machine learning in predicting drug-induced liver injury among tuberculosis patients: model development and validation study. *BMC Med Res Methodol*. 2024; 24(1): 92.
12. Huang C-K, Huang J-Y, Chang C-H, Tsai S-J, Shu C-C, Wang H-C, et al. The effect of statins on the risk of anti-tuberculosis drug-induced liver injury among patients with active tuberculosis: a cohort study. *J Microbiol Immunol Infect*. 2024; 57(3): 498–508.

13. Lewis JH, Korkmaz SY, Rizk CA, Copeland MJ. Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis. *Expert Opin Drug Saf.* 2024; 23(9): 1093–107.
14. Gopalakrishna H, Chalasani N. Drug-induced liver injury due to first-line antituberculosis medications in India: a major hindrance to achieve the goal of tuberculosis elimination. *Indian J Gastroenterol.* 2025; 44(1): 4–7.
15. Tang SJ, Li L. Strengthen the study of anti-tuberculosis drug-induced liver injury in China. *Zhonghua Jie He He Hu Xi Za Zhi.* 2019; 42(5): 323–5.
16. Zhao P, Chen J, Yang YQ, Peng Y. Nomogram model for predicting risk of anti-tuberculosis drug-induced liver injury among inpatients with tuberculosis. *Zhonghua Jie He He Hu Xi Za Zhi.* 2022; 45(2): 171–6.
17. Du Y, Gu J, Yang Y, Chen Y, Wang Y, Mei Z, et al. Efficacy and safety of bicyclol for treating patients with antituberculosis drug-induced liver injury. *Int J Tuberc Lung Dis.* 2024; 28(1): 6–12.
18. Zhong T, Fan Y, Dong X-L, Guo X, Wong KH, Wong W-T, et al. An investigation of the risk factors associated with anti-tuberculosis drug-induced liver injury or abnormal liver functioning in 757 patients with pulmonary tuberculosis. *Front Pharmacol.* 2021; 12: 708522.
19. National Medical Research Center of Phthiopulmonology and Infectious Diseases, Moscow, Kukurika AV, Vasilyeva IA, National Medical Research Center of Phthiopulmonology and Infectious Diseases, Moscow. Risk of drug-induced liver injury in patients with pulmonary tuberculosis and chronic viral hepatitis: systematic review and meta-analysis. *Infectious diseases: News, Opinions, Training.* 2024; 13(2): 86–93.
20. Kivrane A, Ulanova V, Grinberga S, Sevostjanovs E, Viksna A, Ozere I, et al. Exploring variability in rifampicin plasma exposure and development of anti-tuberculosis drug-induced liver injury among patients with pulmonary tuberculosis from the pharmacogenetic perspective. *Pharmaceutics.* 2024; 16(3): 388.